Arbutus Biopharma Corp (ABUS)
3.74
+0.09
(+2.47%)
USD |
NASDAQ |
Nov 14, 12:22
Arbutus Biopharma Free Cash Flow: -71.92M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -71.92M |
| June 30, 2024 | -73.00M |
| March 31, 2024 | -78.92M |
| December 31, 2023 | -86.94M |
| September 30, 2023 | -86.78M |
| June 30, 2023 | -83.74M |
| March 31, 2023 | -83.83M |
| December 31, 2022 | -35.87M |
| September 30, 2022 | -38.41M |
| June 30, 2022 | -35.68M |
| March 31, 2022 | -29.82M |
| December 31, 2021 | -68.34M |
| September 30, 2021 | -63.84M |
| June 30, 2021 | -59.97M |
| March 31, 2021 | -54.20M |
| December 31, 2020 | -51.67M |
| September 30, 2020 | -49.92M |
| June 30, 2020 | -61.46M |
| March 31, 2020 | -70.44M |
| December 31, 2019 | -71.60M |
| September 30, 2019 | -75.48M |
| June 30, 2019 | -65.20M |
| March 31, 2019 | -65.40M |
| December 31, 2018 | -69.00M |
| September 30, 2018 | -62.23M |
| Date | Value |
|---|---|
| June 30, 2018 | -65.01M |
| March 31, 2018 | -55.16M |
| December 31, 2017 | -55.90M |
| September 30, 2017 | -62.80M |
| June 30, 2017 | -61.46M |
| March 31, 2017 | -71.02M |
| December 31, 2016 | -61.88M |
| September 30, 2016 | -63.85M |
| June 30, 2016 | -52.08M |
| March 31, 2016 | -52.51M |
| December 31, 2015 | -58.67M |
| September 30, 2015 | -46.45M |
| June 30, 2015 | -50.21M |
| March 31, 2015 | -40.28M |
| December 31, 2014 | -13.48M |
| September 30, 2014 | -3.935M |
| June 30, 2014 | -0.853M |
| March 31, 2014 | 4.399M |
| December 31, 2013 | -7.462M |
| September 30, 2013 | 30.52M |
| June 30, 2013 | 32.80M |
| March 31, 2013 | 34.11M |
| December 31, 2012 | 32.89M |
| September 30, 2012 | -7.914M |
| June 30, 2012 | -6.457M |
Free Cash Flow Range, Past 5 Years
-86.94M
Minimum
Dec 2023
-29.82M
Maximum
Mar 2022
-62.82M
Average
-66.09M
Median
Free Cash Flow Benchmarks
| Biomarin Pharmaceutical Inc | 300.88M |
| Amicus Therapeutics Inc | -31.51M |
| Ionis Pharmaceuticals Inc | -374.21M |
| GlycoMimetics Inc | -35.72M |
| FibroGen Inc | -202.99M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -20.74M |
| Cash from Investing (Quarterly) | -11.99M |
| Cash from Financing (Quarterly) | 1.775M |
| Free Cash Flow Per Share (Quarterly) | -0.1097 |
| Free Cash Flow to Equity (Quarterly) | -20.74M |
| Free Cash Flow Yield | -10.67% |